Login
Super Investors PGIM Jennison Health Sciences Fund

PGIM Jennison Health Sciences Fund

Prudential Sector Funds, Inc. · net assets $1.39B · 55 holdings as of May 29, 2026. Monthly N-PORT disclosure: the full book, not just equities.

Asset mix

EC: 96.3% · STIV: 3.7%

Financial position

Total assets
$1.41B
Total liabilities
$24.7M
Net assets
$1.39B
Assets attributable to miscellaneous securities
$0
Assets invested in controlled foreign corporations
$0
Borrowings payable within one year
$0
Payable to controlled companies within one year
$0
Payable to other affiliates within one year
$0
Other liabilities payable within one year
$0
Borrowings payable after one year
$0
Payable to controlled companies after one year
$0
Payable to other affiliates after one year
$0
Other liabilities payable after one year
$0
Payables for delayed-delivery investments
$0
Payables for standby commitments
$0
Liquidation preference of outstanding preferred stock
$0

Monthly flows and gains

Month 1 Month 2 Month 3
Sales $7.76M $6.1M $8.5M
Reinvestment $0 $0 $0
Redemptions $27.4M $26M $33M
Net realized gain (non-derivative) $-19.6M $13.6M $24.9M
Net unrealized appreciation (non-derivative) $-68.8M $-4.86M $48.6M

The three months of the reporting period, as filed; month 3 ends May 29, 2026.

Filing details

Registrant
Prudential Sector Funds, Inc.
Registrant CIK
352665
Registrant LEI
549300IPCXL88G4QUI19
Series
PGIM Jennison Health Sciences Fund
Series ID
S000004380
Series LEI
S41LI155RNUZ4KJ9CN75
SEC file number
811-03175
Address
655 Broad Street, Newark, US-NJ, 07102-4077, US
Phone
1-800-225-1852
Form
NPORT-P
Filed
July 27, 2026
Report period ends
November 30, 2026
Report month ends
May 29, 2026
Accession number
000094040026028340
Holding Value % of net assets
Eli Lilly & Company EC $241M 17.35%
Merck & Company Inc EC $84.2M 6.06%
Unitedhealth Group Inc EC $81.5M 5.87%
Thermo Fisher Scientific Inc EC $63.3M 4.56%
Argenx Se EC $49.4M 3.55%
Vertex Pharmaceuticals Inc EC $46.7M 3.37%
Danaher Corp EC $45.6M 3.28%
Intuitive Surgical Inc EC $42.7M 3.07%
Lonza Group Ag EC $41.9M 3.02%
Cvs Health Corp EC $35M 2.52%
(pipa070) Pgim Core Government Money Market Fund STIV $34.7M 2.50%
Insmed Inc EC $31.7M 2.28%
Roivant Sciences Ltd EC $30.7M 2.21%
Stryker Corp EC $29.9M 2.16%
Sionna Therapeutics Inc EC $27.9M 2.01%
Beone Medicines Ltd EC $25.2M 1.82%
Vaxcyte Inc EC $24.6M 1.77%
Align Technology Inc EC $24.3M 1.75%
Agilent Technologies Inc EC $24M 1.73%
Palvella Therapeutics Inc EC $21.7M 1.56%
Apogee Therapeutics Inc EC $19.7M 1.42%
Cabaletta Bio Inc EC $18.8M 1.35%
Prudential Investment Portfolios 9 STIV $18.2M 1.31%
Newamsterdam Pharma Company Nv EC $18M 1.30%
Dianthus Therapeutics Inc EC $17.7M 1.28%
Kymera Therapeutics Inc EC $17.6M 1.26%
Scholar Rock Holding Corp EC $17.4M 1.25%
Celcuity Inc EC $14.8M 1.07%
Revolution Medicines Inc EC $14.8M 1.06%
Astrazeneca PLC EC $14.7M 1.06%
Mineralys Therapeutics Inc EC $14.5M 1.04%
Teva Pharmaceutical Industries Ltd EC $13.9M 1.00%
Xenon Pharmaceuticals Inc EC $13.8M 1.00%
Disc Medicine Inc EC $13.8M 0.99%
Protagonist Therapeutics Inc EC $13.5M 0.97%
Bayer Ag EC $13M 0.94%
Veradermics Inc EC $12.9M 0.93%
Tandem Diabetes Care Inc EC $11.7M 0.84%
Erasca Inc EC $11.3M 0.81%
Crinetics Pharmaceuticals Inc EC $9.86M 0.71%
Tarsus Pharmaceuticals Inc EC $9.66M 0.70%
Immunovant Inc EC $9.25M 0.67%
Avalyn Pharma Inc EC $9.17M 0.66%
Olema Pharmaceuticals Inc EC $8.74M 0.63%
Elanco Animal Health Inc EC $8.56M 0.62%
Arcutis Biotherapeutics Inc EC $8.4M 0.60%
Seaport Therapeutics Inc EC $7.98M 0.57%
Abivax Sa EC $7.5M 0.54%
Uniqure Nv EC $7.14M 0.51%
Lb Pharmaceuticals Inc EC $6.47M 0.47%
Tyra Biosciences Inc EC $6.11M 0.44%
Enliven Therapeutics Inc EC $4.97M 0.36%
Spyre Therapeutics Inc EC $4.71M 0.34%
Oruka Therapeutics Inc EC $4.47M 0.32%
Cabaletta Bio Inc Warrant EC $2.74M 0.20%

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support